Efforts to vaccinate the world’s population against Covid-19 got a boost Friday after research showed that some vaccines provide strong, one-dose protection, and that one of the vaccines can now be stored in normal freezers instead of ultra-cold ones.

The vaccine developed by Pfizer Inc. and BioNTech SE generates robust immunity after one dose, according to new research out of Israel, and further data showed that the University of Oxford and AstraZeneca PLC vaccine similarly prevented Covid-19 when doses were spaced three months apart.

The findings could boost arguments in favor of delaying the second dose of the two-shot vaccine, as the U.K. has done. They could also have substantial implications on vaccine policy and distribution around the world, simplifying the logistics of distributing the vaccines.

Also Friday, Pfizer and BioNTech said they asked U.S. regulators to allow their vaccine to be stored and transported at temperatures consistent with standard freezing, around minus 20 Celsius, following successful internal stability testing. Similar filings were being prepared in other countries.

Should Pfizer’s request be granted by regulators, it would mean its vaccine would vastly expand access in rural regions around the world, as well as pharmacies and physician offices, according to industry experts and officials.

This post first appeared on wsj.com

You May Also Like

5 twists that could upend Democrats’ best-laid plans for the 2024 election

What if something similar were to happen to Biden? A brain freeze…

GE Appliances Turns Up the Speed on Supply-Chain Upgrade

GE washing machines for sale at an appliance store in San Jose,…

EU Plans Curbs to Artificial Intelligence, Facial Recognition

The European Union’s executive arm proposed a bill that would limit police…

Democrats rebrand Build Back Better bill to counter inflation concerns

WASHINGTON — Democrats are refocusing their message on President Joe Biden’s Build…